These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 17467193

  • 1. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
    Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, Rödel C.
    Int J Radiat Oncol Biol Phys; 2007 Jul 15; 68(4):1072-80. PubMed ID: 17467193
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M, Miyanaga N, Tokuuye K, Saida Y, Ohara K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Hattori K, Shimazui T, Akaza H, Akine Y.
    Int J Radiat Oncol Biol Phys; 2006 Apr 01; 64(5):1371-9. PubMed ID: 16580495
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
    Chauvet B, Félix-Faure C, Davin JL, Berger C, Vincent P, Reboul F.
    Cancer Radiother; 1998 Apr 01; 2 Suppl 1():77s-81s. PubMed ID: 9749084
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 01; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 9. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
    Weiss C, Wittlinger M, Engehausen DG, Krause FS, Ott OJ, Dunst J, Sauer R, Rödel C.
    Int J Radiat Oncol Biol Phys; 2008 Apr 01; 70(5):1502-6. PubMed ID: 17935905
    [Abstract] [Full Text] [Related]

  • 10. Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil.
    Rödel C, Grabenbauer GG, Kühn R, Zörcher T, Papadopoulos T, Dunst J, Schrott KM, Sauer R.
    Int J Radiat Oncol Biol Phys; 2002 Apr 01; 52(5):1303-9. PubMed ID: 11955743
    [Abstract] [Full Text] [Related]

  • 11. Updated results of bladder-sparing trimodality approach for invasive bladder cancer.
    Zapatero A, Martin de Vidales C, Arellano R, Bocardo G, Pérez M, Ríos P.
    Urol Oncol; 2010 Apr 01; 28(4):368-74. PubMed ID: 19362865
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ, Toonkel LM, Zietman AL, Tanguay S, Sandler HM.
    Urology; 2009 Apr 01; 73(4):833-7. PubMed ID: 19100600
    [Abstract] [Full Text] [Related]

  • 14. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.
    Wittlinger M, Rödel CM, Weiss C, Krause SF, Kühn R, Fietkau R, Sauer R, Ott OJ.
    Radiother Oncol; 2009 Nov 01; 93(2):358-63. PubMed ID: 19837472
    [Abstract] [Full Text] [Related]

  • 15. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun 01; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 16. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
    Weiss C, von Römer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, Sauer R, Rödel C, Rödel F.
    Int J Radiat Oncol Biol Phys; 2009 Aug 01; 74(5):1455-60. PubMed ID: 19231102
    [Abstract] [Full Text] [Related]

  • 17. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
    Müller AC, Diestelhorst A, Kuhnt T, Kühn R, Fornara P, Scholz HJ, Dunst J, Zietman AL.
    Strahlenther Onkol; 2007 Apr 01; 183(4):177-83. PubMed ID: 17406798
    [Abstract] [Full Text] [Related]

  • 18. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J, Diestelhorst A, Kühn R, Müller AC, Scholz HJ, Fornara P.
    Strahlenther Onkol; 2005 Oct 01; 181(10):632-7. PubMed ID: 16220401
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, Berry MP, Keller J, Tripcony L, Trans Tasman Radiation Oncology Group.
    Radiother Oncol; 2006 Oct 01; 81(1):9-17. PubMed ID: 17011058
    [Abstract] [Full Text] [Related]

  • 20. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
    Poortmans PM, Richaud P, Collette L, Ho Goey S, Pierart M, Van Der Hulst M, Bolla M, EORTC Radiation Oncology Group.
    Acta Oncol; 2008 Oct 01; 47(5):937-40. PubMed ID: 18568488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.